This is default featured slide 1 title

Find drugs, medications, medical conditions, medication evaluator, latest drug news, vitamins & supplements, pill identifier, first aid resources and many more medicine information with prescription.

This is default featured slide 2 title

Find drugs, medications, medical conditions, medication evaluator, latest drug news, vitamins & supplements, pill identifier, first aid resources and many more medicine information with prescription.

This is default featured slide 3 title

Find drugs, medications, medical conditions, medication evaluator, latest drug news, vitamins & supplements, pill identifier, first aid resources and many more medicine information with prescription.

This is default featured slide 4 title

Find drugs, medications, medical conditions, medication evaluator, latest drug news, vitamins & supplements, pill identifier, first aid resources and many more medicine information with prescription.

This is default featured slide 5 title

Find drugs, medications, medical conditions, medication evaluator, latest drug news, vitamins & supplements, pill identifier, first aid resources and many more medicine information with prescription.

Wednesday, April 2, 2014

Ketotifen


Indication

Symptomatic treatment of allergic conditions including rhinitis and conjunctivitis. Prophylactic treatment of
Bronchial asthma

Dosage and Administration

Adults : 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases.
Children above 3 years: 1 mg twice daily with food. Patients known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician. Use in elderly: Same as adult dose or as advised by the physician.

Contraindication and Precaution

A reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly should not be instilled while the patient is wearing lenses.

Side Effect

1-2%: Burning/stinging, punctuate corneal epithelial erosion. <1%: Blurring of vision upon drug instillation, dry eyes, eyelid disorder, conjunctivitis, eye pain, photophobia, subconjunctival haemorrhage.

Use in Pregnancy & Lactation

Systemic levels after ocular administration are much lower than after oral use. Caution should be exercised when prescribing to pregnant women.

Use in Children

Children under 3 years of age: Consult with a doctor.

Preparation

 0.025% Eye Drops.

Thursday, March 27, 2014

Cefuroxime




Indication

Cefuroxime is indicated  in the treatment  of
1. Upper respiratory tract infections: For example, ear, nose and throat infections such as otitis media, sinusitis, tonsillitis and pharyngitis.
2. Lower respiratory tract infections: For example, acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia.
3. Skin and sft tissue infections: Such as furunculosis, pyoderma and impetigo.
4. Genilo-urinary tract infections: Such as pyelonephritis, urethritis and cystitis.
5. Gonorrhoea: Acute uncomplicated gonococcal urethritis and cervicitis.
6. Early lyme disease and subsequent prevention of late Lyme disease.

Pharmacology

Cefuroxime is a well-characterized and effective antibacterial agent, which has broad-spectrum  bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains. Cefuroxime has good stability to bacterial β-lactamase and consequently, is active against many ampicillin-resistant and amoxycillin-resistant strains.

Composition  

Cefuroxime 125 mg tablet: Each film coated tablet contains Cefuroxime 125 mg as Cefuroxime axetil BP.
Cefuroxime 250 mg tablet: Each film coated tablet contains Cefuroxime 250 mg as Cefuroxime axetil BP.
Cefuroxime 500 mg tablet: Each film coated tablet contains Cefuroxime 500 mg as Cefuroxime axetil BP.
Cefuroxime powder for suspension (70 ml): Each 5 ml reconstituted suspension contains 125 mg Cefuroxime, as Cefuroxime axetil BP.
Cefuroxime 750 mg IM/IV injection: Each vial contains Cefuroxime 750 mg, as Cefuroxime sodium BP.
Cefuroxime 1.5 gm IV injection: Each vial contains Cefuroxime 1.5 gm, as Cefuroxime sodium BP.

Dosage and Administration
 
Adults: Most infections well respond to 250 mg b.i.d. In mild to moderate lower respiratory tract infections e.g bronchitis 250 mg b.i.d. should be given. For more severe lower respiratory tract infections or if pneumonia is suspected then 500 mg b.i.d. should be given.
For urinary tract infections a dose of 125 mg b.i.d. is usually adequate, in pyelonephritis the recommended dose is 250 mg b.i.d. A single dose of one gram is recommended for the treatment of uncomplicated gonorrhea.
Lyme disease in adults and children over the age of 12 years: The recommended dose is 500 mg b.i.d. for 20 days.
Children: The usual dose is 125 mg b.i.d. or 10 mg/kg b.i.d. to a maximum of 250 mg daily.
For otitis media, in children less than two years of age the usual dosage is 125 mg b.i.d. or 10 mg/kg b.i.d. to a maximum of 250 mg daily and in children over two years of age 250 mg b.i.d. or 15 mg/kg b.i.d. to a maximum of 500 mg daily.
There is no experience in children under three months of age. The usual course of therapy in seven days. Cefuroxime should be taken after food for optimum absorption.

Parental Dosage

Adults: Cefuroxime 750 mg to 1.5 g IM or IV every 8 hourly, usually 50 to 10 days.
Preoperative prophylaxis: For clean contaminated or potentially contaminated surgical procedures, administer 1.5 g IV prior to surgery ( half to one hour before ). Thereafter, give 750 mg iV or IM every 8 hours when the procedure is prolonged.
Infants and Children (>3 months): 50 to100 mg/kg/day in equally divided doses every 6 to 8 hours. Use 100 mg/kg/day (not to exceed the maximum adult dose) for more severe or serious infections.
Bone and Joint Infections: 150 mg/kg/day (not to exceed the maximum adult dose) in equally divided doses every 8 hours.
Bacterial meningitis: Initially 200 to 240 mg/kg/day IV in divided doses every 8 hours.
Direction for Reconstitution

Cefuroxime 750 mg intramuscular Injection: Add 3 ml water for injection BP and shake gently for dispersion

For 750 mg intravenous injection: Add 6 ml water for injection BP and shake gently for dispersion.
For 1.5 mg intravenous injection: Add 16 ml water for injection BP and shake gently for dispersion.
For Suspension: shake the bottle well before adding water. Then add 35 ml of boiled and cooled water (with the help of the provided cup from different company) to the bottle. Then continue shaking the bottle until the powder is dissolved property.

Contraindication

Cefuroxime is contraindicated in patients with known allergy to Cephalosporins.

Side Effect

Cefuroxime has been associated with nausea and vomiting in a small number of patients.

Acute Over dosage

Excessively large dosage of all cephalosporins can cause cerebral irritation and may cause convulsions. This complication is unlikely to occur in routine practice unless the patient is in renal failure hemodialysis or peritoneal dialysis can remove Cefuroxime.

Precaution

As with antibiotics, prolonged use of Cefuroxime may result in the over growth of non-susceptible organisms (e.g. Canada enterococci, Clostridium difficult), which may require interruption of treatment.

Use in Pregnancy and Lactation

While all antibiotics should be avoided in the first trimester if possible. Cefuroxime has been safety used in later pregnancy to treat urinary and other infections. The placental transfer of Cefuroxime into the fetus was studied in 20 women and therapeutically active concentrations were found in the serum of infants for up to 6 hours after delivery. Cefuroxime is excreted in human milk and consequently caution should be exercised when Cefuroxime is administered to a nursing mother.

Drug Interaction

No potentially hazardous interactions have been reported.

Storage Condition

Tablet: Store below 30 degree C, protected from light and moisture.
Suspension: Store below 25 degree C, protected from light and moisture.
Injection: Store below 25 degree C, protected from light and moisture. Use reconstituted solution immediately. The reconstituted solution is stable for 2 hours at room temperature and for 12 hours when refrigerated at 2 degree to 8 degree Celsius.

How Supplied from different companies

Cefuroxime 125 mg tablet: Box containing 20 tablets in blister pack.
Cefuroxime 250 mg tablet: Box containing 20 tablets in blister pack.
Cefuroxime 500 mg tablet: Box containing 20 tablets in blister pack.
Cefuroxime powder for suspension (70 ml): Bottle containing 70 ml suspension (after reconstitution).

Cefuroxime 750 mg IM/IV injection: Pack of 1 vial containing Cefuroxime 750 mg as Cefuroxime sodium BP accompanied by a solvent ampoule of 10 ml water for injection. It also contains a complementary pouch comprised of disposable syringe (10 ml) needle, alcohol pad and first aid bandage.

Cefuroxime 1.5 gm IV injection: Pack of 1 vial containing Cefuroxime 1.5 gm as Cefuroxime sodium BP accompanied by two solvent ampoule of 10 ml water for injection in each. It also contains a complementary pouch comprised of disposable syringe (20 ml) needle alcohol pad and first aid bandage.

Friday, March 21, 2014

Bromazepam



Description :
Bromazepam is a global anxiolytic with smooth and supprior efficacy. It is one of the benzodiazepines having no side-effects like other benzodiazepines. It effectively manages anxiety and also removes anxiety related various physiological  problems.

Mode of action: 

Bromazepam binds with the specific site on the GABA receptor/chloride channel complex and potentiates the effect of GABA, an important inhibitory transmitter in the CNS which acts by opening chloride ion channels into cells.

Pharmacokinetics:
Peak plasma concentration of Bromazepam is achieved within two hours after oral administration. The absolute bioavailability of the unchanged substance is 60%. On an average 70% of Bromazepam is metabolized in the liver. Bromazepam has an elimination half-life around 20 hours, but the half-life may be longer in elderly subjects. The metabolites are excreted in the urine mainly in conjugated form.

Composition:
Bromazepam tablet: Each tablet contains Bromazepam BP 3 mg
                                                                                         
Indications:
Emotional disturbances: Anxiety and tension states, as adjuvant therapy for anxiety in depressed patients, nervous, tension, restlessness, anxiety and tension related insommia. As an adjuvant to the treatment of an underlying disease responsible for functional or psychosomatic impairments of various organs caused or exacerbated by anxiety and tension.
Cardiovascular and respiratory systems: Pseudo angina pectoris, precordial anxiety, tachycardia, emotiogenic hypertension, dyspnea and hyperventilation; Gastrointestinal tract: irrible bowel syndrome, ulcerative colitis, epigastric pain, spasm, meteorism and diarrhea.
Urogential tract: Irritable bladder, urinary frequency, dysmenorrhoea; Other psychosomatic disturbances: Psychogenic headache, psychogenic dermatoses.
Bromazepam is also suitable for treatment  of anxiety and tension states due to chronic organic diseases and as an adjuvant to psychotherapy in psychoneuroses, acute alcohol withdrawal, adjunct for the relief of muscle spasm.

Dosage and Administration :
1.50mg to 12 mg three times daily according to condition or patient response and  side-effect profile.
Average outpatient dosage: 1.5 mg to 3 mg three times daily.
Severe cases: 6 mg to 12 mg two to three times daily.

Contraindications:
Bromazepam should not be used in case of hypersensitivity of benzodiazepines, respiratory depression, severe hepatic impairment, myasthenia gravis and infant.



Side Effects:
Drowsiness, lightheadedness in the next day; confusion, ataxia and ammesia may occur.

Use in pregnancy and lactation:
The administration of Bromazepam is rarely justified in woman of childbearing potential. Bromazepam should be  avoided during breast-feeding.

Precautions:
Bromazepam should be used cautiously in respiratory diseases, muscle weakness and history of alcohol or drug abuse.

Drug Interactions:
Phenothiazines, barbiturates, MAO inhibitors and psychoactive drugs may potentiate the action of Bromazepam and should not usually be given concurrently.

Overdosage:
Manifestations of overdoage include somnolence, confusion and respiratory and cardiovascular depression with coma in severe cases. 

Storage:

Store in a cool and dry place, protected from light and children’s.